Drugs / BMS-986403
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05244070 | Sep 2022 → May 2023 | B-cell chronic lymphocytic leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05244070 ↗ |